ANZCTR search results

Brief description of the study purpose: This pilot study will examine the feasibility, safety and trends in effectiveness of providing a preoperative hospital and home-based rehabilitation program to individuals with stages I-IIIA Non-small cell lung cancer prior to surgery. The primary aim is to assess the feasibility of the prehabilitation program. Secondary aims are to assess postoperative outcomes (postoperative pulmonary complications and acute hospital Length of stay). Other secondary outcomes include changes in functional exercise capacity, physical activity levels, anxiety and depression and health-related quality of life. Who is it for? You may be eligible to participate in the study if you are over 18 years of age, have suspected stage I-IIIA lung cancer and are presenting for surgery and have no major comorbidities which would make exercise difficult. Study details: Participants will be randomly allocated to intervention or control groups. The intervention consists of preoperative exercise training (aerobic and resistance) for 1-4 weeks prior to lung cancer surgery. The control group will receive standard care (consisting of no preoperative exercise or physiotherapy intervention). It is hoped that this intervention will prove to be feasible and will improve postoperative outcomes, reduced hospital length of stay and improve the preoperative management of people with non-small cell lung cancer.

Paracetamol is one of the most common medications taken in overdose around the world. It is readily available and does not require a prescription to purchase. N-acetylcysteine (NAC) is the antidote used to treat patients at risk of developing liver toxicity secondary to the metabolites of paracetamol that accumulate following paracetamol overdose. The standard NAC treatment regimen lasts 20 to 21 hours and requires admission to hospital. Patients who present to hospital and receive NAC for paracetamol overdose and have normal liver function and subsequently have a less than therapeutic paracetamol concentration and normal liver function with at least 12 hours of treatment with NAC are unlikely to go on to develop liver toxicity. All study participants will be required to stay in hospital for the usual 20 hours (the time for a standard NAC infusion as per the current treatment guidelines) and will have liver function tests measured at this time. This trial aims to determine that a shorter treatment regimen (12 hrs) for paracetamol overdose is safe.

Paracetamol is one of the most common medications taken in overdose around the world. It is readily available and does not require a prescription to purchase. N-acetylcysteine (NAC) is the antidote used to treat patients at risk of developing liver toxicity secondary to the metabolites of paracetamol that accumulate following paracetamol overdose. The standard NAC treatment regimen lasts 20 to 21 hours and requires admission to hospital. Patients who present to hospital and receive NAC for paracetamol overdose and have normal liver function and subsequently have a less than therapeutic paracetamol concentration and normal liver function with at least 12 hours of treatment with NAC are unlikely to go on to develop liver toxicity. Conversely, patients who present late (greater than 8 hours post ingestion) to hospital, or with abnormal liver function, high paracetamol concentration and require NAC treatment, are likely to require a prolonged course of treatment and might develop liver failure. We aim to increase the dose of NAC in this high risk group and examine whether this decreases degree of liver injury and hospital length of stay.

Cellulite is as an "orange peel" appearance on the skin surface that is associated with poor microcirculation, weight change, race and heredity, but there is little consensus about its cause. The objective of this study is to determine the effect of a caffeine cream that we have developed on cellulite appearance, thigh circumference and skin fold thickness. We will also assess participants' perception of the sensorial qualities of the caffeine cream. Participants will apply the cream to one thigh and a placebo cream to the other thigh twice daily for 12 weeks. Assessments will be done at week 4, 8 and 12. We anticipate that the developed cream will target caffeine to the skin tissue and reduce cellulite.

Several studies have been completed in countries other than Australia comparing urinary iodine concentration and iodine intake in omnivores, vegetarians and vegans. It has been found that plant based diets are lower in iodine in these studies. Dairy is one of the first or second main sources of iodine in the Australian diet, while it is variable depending on geographic location and supplementary feeding practices. Plant milks are currently low in iodine and are subject to fortification restrictions in Australia. The research may help to update fortification guidelines for plant based products. The hypothesis is that the plant based group will have a lower urinary concentration of iodine.

The AMMEND study is a 3-month randomised control trial testing the effect of a Mediterranean diet (MD) on the symptoms of depression in young men. Participants will be randomly allocated to either the MD group or the control group, which consists of a social support “befriending” protocol, via a computer-generated block randomisation sequence. At the baseline appointment participants will complete a number of questionnaires and baseline measurements which will be recorded in the Case Report Form, including the Becks Depression Inventory depression scale and a short Dietary Screener Questionnaire (DSQ). Participants will have scheduled follow up appointments at 6 weeks and 12 weeks. Participants in the MD group will complete Diet History Forms to check levels of adherence to the diet and will be scored against the MD Adherence Score. The main outcome measure will be any changes to the BDI depression scale results. At the conclusion of the trial, participants in the MD group will complete a short, electronic, self-administered survey assessing their experiences and perceived benefits and challenges of continuing to follow a Mediterranean diet long term.

The research project is testing a potential new treatment for psoriasis (an inflammatory skin condition) called IMU-935. Before a new medicine can be approved for use in humans, it is necessary to confirm that it is safe and effective. This is done by carrying out clinical research studies such as this one. The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of IMU-935. The pharmacokinetics (PK) of IMU-935 in humans will also be determined. PK testing involves taking blood and urine samples to measure how much of the drug gets into the blood stream, and how long the body takes to get rid of it. When testing for PK, the sample will also be tested for metabolites (breakdown products) of IMU-935.

The purpose of this study is to determine if shared decision making involving the patient, medical team and their support person will be of benefit to a patient in order to identify what is really important in their life. This initially involves approximately a 15 minute telephone conversation talking about the study and what to expect at the multidisciplinary shared decision making meeting. If an inpatient, a bedside conversation will occur to discuss surgical risks and benefits and the next steps. The study centres around informed decisions about their surgery and how they would like to be cared for. Who is it for? You may be eligible for this study if you are older than 65 or older than 45 (if Aboriginal or Torres Strait Islander) and undergoing Major General or Vascular Elective or Semi-urgent surgery. Study details Patients in this study will be randomly assigned to either the control group (standard treatment) or the intervention group. Participants in the intervention group will be involved in a 'shared decision making' team meeting, involving relevant medical professionals and support persons of the patient. Part of involvement in the study will include a variety of questionnaires about surgery decision making and quality of life. It is hoped that this research will help determine how comfortable patients feel about making decision about their healthcare and also assist the medical community in developing strategies for shared decision making.

The purpose of the present study is to evaluate a family-oriented, cognitive behavioural intervention relative to treatment as usual for the treatment of anxiety with children and adolescents meeting diagnostic criteria for an anxiety disorder in a real world clinical setting (the Mater Day Program), The study will compare 2 experimental conditions, namely (1) treatment as usual at the Mater Day Program; and (2) treatment as usual plus an anxiety intervention (consisting of a child-focused program and a parent-focused program). It is hypothesised that the second condition will be significantly more effective in terms of children's diagnostic status; children's self-reported anxiety and depression; overall levels of functional impairment; and parental reports of their child's anxiety. Given the limited number of studies examining the outcomes of family-oriented CBT interventions for anxiety relative to treatment as usual in child and youth mental health settings, along with the paucity of research involving young people with complex and comorbid mental health diagnoses, this study aims to contribute novel information to the current research base.

Food addiction is an emerging area of research. We are interested in developing a novel intervention for those with addictive eating behaviours in Australia. This project will determine if a new personality targeted brief intervention (3 month) targeting in food addiction reduces addictive eating behaviors, improves dietary intake and improves quality of life . The intervention will be delivered via telehealth/phone